AI-061
- Generic Name
- AI-061
Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- MelanomaNon Small Cell Lung CancerHead and Neck Squamous Cell CarcinomaHigh Grade Serous Adenocarcinoma of OvaryPrimary Peritoneal CarcinomaFallopian Tube CancerEndometrial CancerCervical CancerRenal Cell CarcinomaBladder Cancer
- Interventions
- First Posted Date
- 2023-05-15
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- OncoC4, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05858736
- Locations
- 🇦🇺
St. Vincent's Private Hospital, Darlinghurst, New South Wales, Australia
🇦🇺Mater Misericordiae Ltd., Brisbane, Queensland, Australia
🇦🇺Tasman Oncology Research, Southport, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath